MedPath

The examination of appropriate switching dose of epoetin beta pegol from short-acting epoetin in the treatment of anemia in the patients on chronic hemodialysis.

Not Applicable
Conditions
Patients on chronic hemodialysis
Registration Number
JPRN-UMIN000007839
Lead Sponsor
Apheresis and Dialysis Center Keio University, School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with severe heart failure Patients who can not be obtained written informed consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hemoglobin concentration, dose of epoetin beta pegol
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath